Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China · Delayed Price · Currency is CNY 10.09
+0.02 (0.20%)
Jan 23, 2026, 3:04 PM CST
Xiangxue Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -1,003 | -858.56 | -388.96 | -530.06 | -688.47 | 98.42 | Upgrade |
Depreciation & Amortization | 223.58 | 223.58 | 237.3 | 239.39 | 149.91 | 135.32 | Upgrade |
Other Amortization | 19.59 | 19.59 | 8.04 | 7.69 | 14.98 | 14.51 | Upgrade |
Loss (Gain) From Sale of Assets | -6.99 | -6.99 | 0.09 | -4.88 | -2.34 | 3.57 | Upgrade |
Asset Writedown & Restructuring Costs | 334.92 | 334.92 | 105.38 | 129.73 | 444.56 | 1.11 | Upgrade |
Loss (Gain) From Sale of Investments | 4.89 | 4.89 | 60.01 | -47.32 | -49.23 | -20.47 | Upgrade |
Other Operating Activities | 482.97 | 275.44 | 270.71 | 249.13 | 269.71 | 187.12 | Upgrade |
Change in Accounts Receivable | -54.74 | -54.74 | 62.89 | -106.33 | -14.75 | -491.12 | Upgrade |
Change in Inventory | -7.27 | -7.27 | 9.62 | 18.65 | 42.85 | -83.4 | Upgrade |
Change in Accounts Payable | 52.61 | 52.61 | -126.51 | 266.28 | 86.44 | 388.24 | Upgrade |
Change in Other Net Operating Assets | 33.02 | 33.02 | 17.11 | 21.76 | -1.66 | 5.32 | Upgrade |
Operating Cash Flow | 81.61 | 18.17 | 263.44 | 227.38 | 257.56 | 257.18 | Upgrade |
Operating Cash Flow Growth | 131.13% | -93.10% | 15.86% | -11.72% | 0.15% | 209.78% | Upgrade |
Capital Expenditures | -20.63 | -35.24 | -56.03 | -367.27 | -562.74 | -756.01 | Upgrade |
Sale of Property, Plant & Equipment | 0.34 | 30.41 | - | 24.71 | 0.17 | 2.47 | Upgrade |
Cash Acquisitions | - | - | - | - | -154.32 | - | Upgrade |
Divestitures | 24.91 | 41.26 | 0.36 | 435.74 | 59.35 | 71.53 | Upgrade |
Investment in Securities | -1.21 | 23.44 | 1.53 | 26.42 | 864.36 | -12.23 | Upgrade |
Other Investing Activities | -9.78 | -24.91 | 0.48 | 259.67 | -319.63 | 0.68 | Upgrade |
Investing Cash Flow | -6.38 | 34.96 | -53.66 | 379.26 | -112.8 | -1,287 | Upgrade |
Short-Term Debt Issued | - | - | - | - | 206.36 | 148.52 | Upgrade |
Long-Term Debt Issued | - | 224.48 | 379.48 | 1,151 | 4,406 | 3,409 | Upgrade |
Total Debt Issued | 241.28 | 224.48 | 379.48 | 1,151 | 4,612 | 3,557 | Upgrade |
Long-Term Debt Repaid | - | -206.62 | -429.19 | -1,468 | -4,881 | -2,210 | Upgrade |
Total Debt Repaid | -223.01 | -206.62 | -429.19 | -1,468 | -4,881 | -2,210 | Upgrade |
Net Debt Issued (Repaid) | 18.27 | 17.86 | -49.71 | -316.96 | -269.06 | 1,347 | Upgrade |
Issuance of Common Stock | - | - | - | - | - | 0.9 | Upgrade |
Repurchase of Common Stock | - | - | - | -0.27 | -0.38 | - | Upgrade |
Common Dividends Paid | -0.37 | -50.55 | -140.66 | -175.8 | -216.91 | -204.94 | Upgrade |
Other Financing Activities | -39.74 | -35.26 | -10.26 | -159.74 | 36.13 | 30.28 | Upgrade |
Financing Cash Flow | -21.84 | -67.95 | -200.63 | -652.77 | -450.22 | 1,173 | Upgrade |
Foreign Exchange Rate Adjustments | -0 | 0 | -0 | 0.9 | -0.09 | -0.38 | Upgrade |
Net Cash Flow | 53.39 | -14.81 | 9.15 | -45.23 | -305.56 | 143.21 | Upgrade |
Free Cash Flow | 60.98 | -17.07 | 207.41 | -139.89 | -305.18 | -498.83 | Upgrade |
Free Cash Flow Margin | 4.15% | -0.92% | 9.02% | -6.40% | -10.27% | -16.24% | Upgrade |
Free Cash Flow Per Share | 0.09 | -0.03 | 0.32 | -0.21 | -0.46 | -0.76 | Upgrade |
Cash Income Tax Paid | 56.03 | 95.72 | 72.13 | 65.98 | 116.17 | 111.69 | Upgrade |
Levered Free Cash Flow | 689.95 | 554.16 | 16.29 | 28.83 | 52.33 | 1,282 | Upgrade |
Unlevered Free Cash Flow | 857.84 | 699.69 | 164.46 | 162.08 | 178.62 | 1,363 | Upgrade |
Change in Working Capital | 25.31 | 25.31 | -29.13 | 183.69 | 118.44 | -162.4 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.